[Clinical and immunological studies in borderline mental disorders: problems and solutions].
The study demonstrated that patients having an acute response to stress and those with adaptative disorders with prevailing short-term depressive disorders had certain immunological disorders. Therapy with tranquilizers indicated that they produced an inhibitory effect on T- and B-cell immunity, antibody formation and lymphokine production. Among the immunomodulating peptides myelopid, licopid, and Tactivin, the former was found to be the most effective against anxiety and fear while licopid was the most effective agent in the treatment of psychoasthenic disorders. The findings suggest that therapy with psychotropic peptides will open new vistas in treating mental disorders.
Aleksandrovskiĭ
Iu A
IuA
Chekhonin
V P
VP
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000627:therapeutic use; D028341:Activins; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D001853:Bone Marrow; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy / Q000276:immunology*; D009842:Oligopeptides; D010455:Peptides / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D013949:Thymus Extracts / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000627:therapeutic use; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D009842:Oligopeptides; D010455:Peptides; D013949:Thymus Extracts; D014149:Tranquilizing Agents; C044147:activin B; D028341:Activins; C048617:myelopeptides; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C036191:T-activin